# ATOSSA THERAPEUTICS, INC. (ATOS) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_9a22c88d3ca90f255565 · retrieved 2026-08-12T07:21:38.540Z

## Overview
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, with its lead product candidate (Z)-endoxifen currently in development across several clinical settings.

Atossa Therapeutics entered into a securities purchase agreement with institutional investors for a registered direct offering. The company issued 1,363,637 shares of common stock and Series A warrants to purchase up to 1,363,637 shares of common stock, plus short-term Series B warrants to purchase up to 1,363,637 shares of common stock. The offering raised $4.5 million in upfront gross proceeds, with the potential to receive up to an additional $12 million upon full cash exercise of the warrants, for a total potential of $16.5 million in gross proceeds. Net proceeds are designated to support the clinical development of (Z)-endoxifen and for general corporate working capital.

## Terms
- Counterparty: Institutional investors · Deal value: $16.5M · Consideration: mixed

## Key dates
- Announced 2026-08-07

## Timeline
- 2026-08-07 · 8-K (0001193125-26-339292): 8-K - ATOSSA THERAPEUTICS, INC. — *Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need, with its lead product candidate (Z)-endoxifen currently in development across several clinical settings.* Atossa Therapeutics entered into a securities purchase agreement with institutional investors for a registered direct offering. The company issued 1,363,637 shares of common stock and Series A warrants to purchase up to 1,363,637 shares of common stock, plus short-term Series B warrants to purchase up to 1,363,637 shares of common stock. The offering raised $4.5 million in upfront gross proceeds, with the potential to receive up to an additional $12 million upon full cash exercise of the warrants, for a total potential of $16.5 million in gross proceeds. Net proceeds are designated to support the clinical development of (Z)-endoxifen and for general corporate working capital.
  https://www.sec.gov/Archives/edgar/data/1488039/0001193125-26-339292.txt

## Citations
- 0001193125-26-339292 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526339292